Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
McKesson
Harvard Business School
Colorcon
Express Scripts

Last Updated: July 5, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for BGJ398


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug BGJ398?

BGJ398 is an investigational drug.

There have been 19 clinical trials for BGJ398. The most recent clinical trial was a Phase 2 trial, which was initiated on December 31st 2018.

The most common disease conditions in clinical trials are Neoplasms, Carcinoma, and Cholangiocarcinoma. The leading clinical trial sponsors are Novartis Pharmaceuticals, National Cancer Institute (NCI), and M.D. Anderson Cancer Center.

There are thirty-eight US patents protecting this investigational drug and five hundred and sixty international patents.

Recent Clinical Trials for BGJ398
TitleSponsorPhase
Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene MutationsNational Cancer Institute (NCI)Phase 2
Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene MutationsSameek RoychowdhuryPhase 2
Infigratinib Before Surgery for the Treatment of Upper Tract Urothelial CancerNational Cancer Institute (NCI)Phase 1/Phase 2

See all BGJ398 clinical trials

Clinical Trial Summary for BGJ398

Top disease conditions for BGJ398
Top clinical trial sponsors for BGJ398

See all BGJ398 clinical trials

US Patents for BGJ398

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
BGJ398   Start Trial FGFR inhibitor for use in the treatment of hypophosphatemic disorders Novartis AG (Basel, CH)   Start Trial
BGJ398   Start Trial Antibody drug conjugates Novartis AG (Basel, CH)   Start Trial
BGJ398   Start Trial Pharmaceutical combinations Novartis AG (Basel, CH)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Medtronic
AstraZeneca
Johnson and Johnson
McKinsey
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.